Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

NCT07703436 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT07703436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07703436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
March 31, 2032
Enrollment
40 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma idh mutant grade 2, astrocytoma idh mutant grade 3, glioma, grade 2 idh1-mutant glioma, grade 3 idh1-mutant glioma, idh1-mutant glioma, oligodendroglioma, oligodendroglioma idh-1 mutant and 1/p19q-codeleted